Myeloid progenitors: A radiation countermeasure that is effective when initiated days after irradiation

Radiation Research

Volumn 177, Issue 6, 2012, Pages 781-791

  Singh, Vijay K ^a,b   Christensen, Julie ^c   Fatanmi, Oluseyi O ^a   Gille, Daphne ^c   Ducey, Elizabeth J ^a   Wise, Stephen Y ^a   Karsunky, Holger ^c   Sedello, Anna K ^c  

^a ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c Cellerant Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT 60;

ACUTE RADIATION SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; EX VIVO STUDY; GAMMA RADIATION; HAPLOTYPE; HEMATOPOIETIC TISSUE; IRRADIATION; LETHAL DOSE; MALE; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; SURVIVAL RATE; X RAY;

ACUTE RADIATION SYNDROME; ANIMALS; CELLS, CULTURED; CRYOPRESERVATION; CYTOKINES; GAMMA RAYS; MALE; MICE; MYELOID PROGENITOR CELLS; RADIATION DOSAGE; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE THERAPY; X-RAYS;

MUS;

EID: 84863220077     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2894.1     Document Type: Article

References (44)

1. Carter AB, May MM, Perry WJ. The day after: Action following a nuclear blast in a U.S. city. Washington Quarterly 2007; 30:19-32.
2. Hall EJ, Giaccia AJ. Radiobiology for the Radiobiologist. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006.
3. Hill RP. Radiation effects on the respiratory system. British Journal of Radiology Suppl. 2005; 27:75-81.
4. Fliedner TM, Dorr DH, Meineke V. Multi-organ involvement as a pathogenetic principle of the radiation syndromes: a study involving 110 case histories documented in SEARCH and classified as the bases of haematopoietic indicators of effect. Brit J Radiol Suppl. 2005; 27:1-8.
5. Moulder JE, Cohen EP. Radiation-induced multi-organ involvement and failure: the contribution of radiation effects on the renal system. Brit J Radiol Suppl. 2005; 27:82-8.
6. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 2004; 162:711-28. (Pubitemid 39552901)
7. Dumont F, Le Roux A, Bischoff P. Radiation countermeasure agents: an update. Expert Opinion Therapeut Pat 2010; 20:73-101.
8. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241:58-62.
9. Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL. Identification of a lineage of multipotent hematopoietic progenitors. Development 1997;124:1929-39. (Pubitemid 27270262)
10. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997; 91:661-72. (Pubitemid 27513657)
11. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404:193-7. (Pubitemid 30154488)
12. BitMansour A, Burns SM, Traver D, Akashi K, Contag CH, Weissman IL, et al. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood 2002; 100:4660-7. (Pubitemid 35429712)
13. Arber C, BitMansour A, Sparer TE, Higgins JP, Mocarski ES, Weissman IL, et al. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 2003;102:421-8. (Pubitemid 36841955)
14. Na Nakorn T, Traver D, Weissman IL, Akashi K. Myeloerythroidrestricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest 2002; 109:1579-85. (Pubitemid 34663520)
15. BitMansour A, Cao T, Chao S, Shashidhar S, Brown JMY. Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia. Blood 2008; 105:3535-7. (Pubitemid 40628196)
16. Arber C, Bitmansour A, Shashidhar S, Wang S, Tseng B, Brown JM. Protection against lethal Aspergillus fumigatus infection in mice by allogeneic myeloid progenitors is not major histocompatibility complex restricted. J Infect Dis 2005; 192:1666-71. (Pubitemid 41504705)
17. Singh VK, Brown DS, Fatanmi OO, Parekh VI, Gille DA, Whitnall MH, et al. Myeloid progenitor cells as an effective treatment for acute radiation syndrome. 55th Annual Meeting of the Radiation Research Society. Savannah, GA; 2009.
18. Singh VK, Ducey EJ, Brown DS, Whitnall MH. A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute. Int J Radiat Biol 2012; 88:296-310.
19. Montgomery Jr CA. Control of animal pain and distress in cancer and toxicologic research. J Am Vet Med Assoc 1987; 191:1277-81.
20. Tomasivic SP, Coghlan LG, Gray KN, Mastromarino AJ, Travis EL. IACUC evaluation of experiments requiring death as an end point: a cancer center's recommendations. Lab Animal 1988; January/February:31-4.
21. Smith-Berdan S, Gille D, Weissman IL, Christensen JL. Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood 2007; 110:1370-8. (Pubitemid 47281439)
22. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1994; 1:661-73. (Pubitemid 124000730)
23. Singh PK, Wise SY, Ducey EJ, Fatanmi OO, Elliott TB, Singh VK. Tocopherol succinate protects mice against radiation-induced gastrointestinal injury. Radiat Res 2011; 177:133-45.
24. ISO-ASTM. Standard practice for use of an alanine dosimetry. ISO/ASTM International Standard. 2004:51607.
25. Nagy V. Accuracy considerations in EPR dosimetry. Appl Radiat Isot 2000; 52:1039-50. (Pubitemid 30209973)
26. Singh VK, Brown DS, Kao TC. Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocytecolony stimulating factor. Int J Radiat Biol 2010; 86:12-21.
27. Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, et al. CBLB613: A TLR 2/6 Agonist, Natural Lipopeptide of Mycoplasma arginini, as a Novel Radiation Countermeasure. Radiat Res 2012; 177:628-42.
28. Seed TM. Radiation protectants: current status and future prospects. Health Phys 2005; 89:531-45. (Pubitemid 41463887)
29. Pellmar TC, Rockwell S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 2005; 163:115-23. (Pubitemid 40039952)
30. Weiss JF, Landauer MR. History and development of radiationprotective agents. Int J Radiat Biol 2009; 85:539-73.
31. Mettler FA, Jr., Voelz GL. Major radiation exposure-what to expect and how to respond. N Engl J Med 2002; 346:1554-61. (Pubitemid 34755696)
32. Benjamin GC, McGeary M, McCutchen SR. Assessing Medical Preparedness to Respond to a Terrorist Nuclear Event: Workshop Report. Washington, D.C. The National Academies Press; 2009.
33. Singh VK, Brown DS, Kao TC, Seed TM. Preclinical development of a bridging therapy for radiation casualties. Exp Hematol 2010; 38:61-70.
34. Singh VK, Shafran RL, Inal CE, Jackson III WE, Whitnall MH. Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. Immunopharmacol Immunotoxicol 2005; 27:521-34. (Pubitemid 43220922)
35. Singh VK, Grace MB, Jacobsen KO, Chang CM, Parekh VI, Inal CE, et al. Administration of 5-androstenediol to mice: pharmacokinetics and cytokine gene expression. Exp Mol Pathol 2008; 84:178-88.
36. Singh VK, Grace MB, Parekh VI, Whitnall MH, Landauer MR. Effects of genistein administration on cytokine induction in wholebody gamma irradiated mice. Int Immunopharmacol 2009; 9:1401-10.
37. Farese AM, MacVittie TJ, Roskos L, Stead RB. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF. Stem Cells 2003;21:79-89. (Pubitemid 36120368)
38. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18:2522-8. (Pubitemid 30432517)
39. Singh PK, Wise SY, Ducey EJ, Brown DS, Singh VK. Radioprotective efficacy of tocopherol succinate is mediated through granulocyte-colony stimulating factor. Cytokine 2011; 56:411-21.
40. Schooltink H, Rose-John S. Cytokines as therapeutic drugs. J Interferon Cytokine Res 2002; 22:505-16. (Pubitemid 34639141)
41. Lotz M. Interleukin-6: a comprehensive review. Cancer Treat Res 1995; 80:209-33.
42. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011; 41:1203-17.
43. Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 2011; 134:8-16.
44. Mason KA, Withers HR, McBride WH, Davis CA, Smathers JB. Comparison of the gastrointestinal syndrome after total-body or total-abdominal irradiation. Radiat Res 1989; 117:480-8. (Pubitemid 19100298)